Here's a dozen pending IPCI pipeline catalysts/valuation drivers to consider that could easily hit at any given time now forward mrock>>>
1. FDA approval of Effexor which has already surpassed 3 and a half years of the FDA's ANDA timeline to approval process
2. FDA approval of Protonix which has already surpassed 3 and a half years of the FDA's ANDA timeline to approval process
3. FDA approval of Seroquel which has already surpassed 3 and a half years of the FDA's ANDA timeline to approval process
4. Positive Rexista study update and movement towards Phase 3 this calendar year(Regabatin trial updates and movement towards Phase 3 as well)
5. Potential new partnership/licensing agreement on Effexor with large up front payment and large milestone payments.
6. Potential new partnership/licensing agreement on Protonix with large up front payment and large milestone payments.
7. Potential new partnership/licensing agreement on Seroquel with large up front payment and large milestone payments.
8. Record fiscal Q1 earnings hitting that provide proof positive results that IPCI has indeed transformed into profitability as of the end of February 2014
9. Phenomenal forward guidance following Q1 earnings
10. Strong expectation that IPCI will soon be ringing the Nasdaq Opening Bell once again...as already promised by IPCI themselves on 1 of their next milestone achievements.
11. IPCI expects to have 2 new ANDA's filed this calendar year...with their stated goal being up to four ANDA Filings per year.
12. IPCI may also choose to proceed with developing the value of any 1 of their next pipeline of ANDA's in house...and then license them out for full commercialization for even more lucrative returns than partnership/licensing agreements...as alluded to as a strong possibility at this past Monday's Roth Conference
News 
Market Data 
Discover 
